Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28126333

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2017 Mar 4
First author
Soria JC

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Mar 4;389(10072):884-886. doi: 10.1016/S0140-6736(17)30124-1.
    note
    Source null
    related pmid
    28126330
    relationship
    Comment in
  2. citation
    Lancet. 2017 Mar 4;389(10072):908. doi: 10.1016/S0140-6736(17)30603-7.
    note
    Source null
    related pmid
    28271844
    relationship
    Erratum in
  3. citation
    J Thorac Dis. 2017 May;9(5):E447-E450. doi: 10.21037/jtd.2017.04.43.
    note
    Source null
    related pmid
    28616306
    relationship
    Comment in

Authors and identifiers

  1. name
    Soria JC
    type
    Author
  2. name
    Tan DSW
    type
    Author
  3. name
    Chiari R
    type
    Author
  4. name
    Wu YL
    type
    Author
  5. name
    Paz-Ares L
    type
    Author
  6. name
    Wolf J
    type
    Author
  7. name
    Geater SL
    type
    Author
  8. name
    Orlov S
    type
    Author
  9. name
    Cortinovis D
    type
    Author
  10. name
    Yu CJ
    type
    Author
  11. name
    Hochmair M
    type
    Author
  12. name
    Cortot AB
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Soria JC
    type
    Author
  2. name
    Tan DSW
    type
    Author
  3. name
    Chiari R
    type
    Author
  4. name
    Wu YL
    type
    Author
  5. name
    Paz-Ares L
    type
    Author
  6. name
    Wolf J
    type
    Author
  7. name
    Geater SL
    type
    Author
  8. name
    Orlov S
    type
    Author
  9. name
    Cortinovis D
    type
    Author
  10. name
    Yu CJ
    type
    Author
  11. name
    Hochmair M
    type
    Author
  12. name
    Cortot AB
    type
    Author
bibliography ids
  1. nci-bib-d97bcf64e671c266ef40d109
book metadata
content sha256
371c16a8cb8e13d0df27395c95d8446da3740038bb8f2d013edad4f38899aba6
document type
citation
dois
  1. 10.1016/S0140-6736(17)30123-X
electronic publication date
display
2017 Jan 24
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28126333
immutable id
pubmed:28126333@371c16a8cb8e13d0df27395c95d8446da3740038bb8f2d013edad4f38899aba6
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10072
name
Lancet (London, England)
nlm unique id
2985213R
pages
917-929
volume
389
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2017 Mar 4;389(10072):884-886. doi: 10.1016/S0140-6736(17)30124-1.
    note
    Source null
    related pmid
    28126330
    relationship
    Comment in
  2. citation
    Lancet. 2017 Mar 4;389(10072):908. doi: 10.1016/S0140-6736(17)30603-7.
    note
    Source null
    related pmid
    28271844
    relationship
    Erratum in
  3. citation
    J Thorac Dis. 2017 May;9(5):E447-E450. doi: 10.21037/jtd.2017.04.43.
    note
    Source null
    related pmid
    28616306
    relationship
    Comment in
outcomes validated
false
pmid
28126333
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
95e44ca47f4c5d0720039c6fac72dbe7cdecd6f30807638b5ad8aeb94548aeba
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Mar 4
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28126333/
title
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Preserved source evidence · Not medical advice